Skip to main content
Top
Published in: Annals of Surgical Oncology 9/2014

01-09-2014 | Pancreatic Tumors

The Impact of Postoperative Complications on the Administration of Adjuvant Therapy Following Pancreaticoduodenectomy for Adenocarcinoma

Authors: Wenchuan Wu, MD, Jin He, MD, PhD, John L. Cameron, MD, Martin Makary, MD, Kevin Soares, MD, Nita Ahuja, MD, Neda Rezaee, MD, Joseph Herman, MD, Lei Zheng, MD, Daniel Laheru, MD, Michael A. Choti, MD, Ralph H. Hruban, MD, Timothy M. Pawlik, MD, PhD, MPH, Christopher L. Wolfgang, MD, PhD, Matthew J. Weiss, MD

Published in: Annals of Surgical Oncology | Issue 9/2014

Login to get access

Abstract

Background

The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy (PD) for adenocarcinoma is still unclear.

Methods

A retrospective review of all patients undergoing PD at our institution between 1995 and 2011 was performed. Clinicopathological data, including Clavien–Dindo complication grade, time to adjuvant therapy (TTA), and survival, were analyzed.

Results

A total of 1,144 patients underwent PD for adenocarcinoma between 1995 and 2011. The overall complication rate was 49.1 % and clinically severe complications (≥IIIb) occurred in 4.2 %. Overall, 621 patients (54.3 %) were known to have received adjuvant therapy. The median TTA was 60 days. Although the presence of a complication was associated with a delay in TTA (p = 0.002), the grade of complication was not (p = 0.112). On multivariate analysis, only age > 68 years (p < 0.001) and length of stay >9 days (p = 0.002) correlated with no adjuvant therapy. Patients with postoperative complications were more likely to receive single adjuvant chemotherapy or radiation therapy (31.4 %) than were patients without complications (17.1 %; p < 0.001). Patients without a complication had a longer median survival compared with patients who experienced complications (19.5 vs. 16.1 months; p = 0.001). Patients without complications who received adjuvant therapy had longer median survival than patients with complications who received no adjuvant therapy (22.5 vs. 10.7 months; p < 0.001). Multivariate analysis demonstrated that complications [hazard ratio (HR) 1.16; p = 0.023] and adjuvant therapy (HR 0.67; p < 0.001) were related to survival.

Conclusion

Complications and no adjuvant therapy are common following PD for adenocarcinoma. Postoperative complications delay TTA and reduce the likelihood of multimodality adjuvant therapy. Identifying patients at increased risk for complications and those unlikely to receive adjuvant therapy warrants further investigation as they may benefit from a neoadjuvant approach.
Literature
1.
2.
go back to reference Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–79.PubMedCrossRef Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–79.PubMedCrossRef
3.
go back to reference Murakami Y, Uemura K, Sudo T, et al. Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic carcinoma after surgical resection. Cancer Chemother Pharmacol. 2013;71:419–29.PubMedCrossRef Murakami Y, Uemura K, Sudo T, et al. Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic carcinoma after surgical resection. Cancer Chemother Pharmacol. 2013;71:419–29.PubMedCrossRef
4.
go back to reference Herman JM, Swartz MJ, Hsu CC, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008;26:3503–10.PubMedCentralPubMedCrossRef Herman JM, Swartz MJ, Hsu CC, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008;26:3503–10.PubMedCentralPubMedCrossRef
5.
go back to reference Hsu CC, Herman JM, Corsini MM, et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: The Johns Hopkins Hospital-Mayo Clinic Collaborative Study. Ann Surg Oncol. 2010;17:981–90.PubMedCentralPubMedCrossRef Hsu CC, Herman JM, Corsini MM, et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: The Johns Hopkins Hospital-Mayo Clinic Collaborative Study. Ann Surg Oncol. 2010;17:981–90.PubMedCentralPubMedCrossRef
6.
go back to reference Murakami Y, Uemura K, Sudo T, et al. Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma. J Am Coll Surg. 2010;211:196–04.PubMedCrossRef Murakami Y, Uemura K, Sudo T, et al. Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma. J Am Coll Surg. 2010;211:196–04.PubMedCrossRef
7.
go back to reference Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10:1199–11.PubMedCrossRef Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10:1199–11.PubMedCrossRef
8.
go back to reference Foo ML, Gunderson LL, Nagorney DM, et al. Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation? fluorouracil. Int J Radiat Oncol Biol Phys. 1993;26:483–89.PubMedCrossRef Foo ML, Gunderson LL, Nagorney DM, et al. Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation? fluorouracil. Int J Radiat Oncol Biol Phys. 1993;26:483–89.PubMedCrossRef
9.
go back to reference Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–10.PubMedCrossRef Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–10.PubMedCrossRef
10.
go back to reference Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection. JAMA. 2010;304:1073–81.PubMedCrossRef Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection. JAMA. 2010;304:1073–81.PubMedCrossRef
11.
go back to reference Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer. JAMA. 2007; 297:267–77.PubMedCrossRef Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer. JAMA. 2007; 297:267–77.PubMedCrossRef
12.
go back to reference Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival: a prospective, single-institution experience. Ann Surg. 1997;225:621–33;discussion 633–6.PubMedCentralPubMedCrossRef Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival: a prospective, single-institution experience. Ann Surg. 1997;225:621–33;discussion 633–6.PubMedCentralPubMedCrossRef
13.
go back to reference Cheung WY, Neville BA, Earle CC. Etiology of delays in the initiation of adjuvant chemotherapy and their impact on outcomes for stage II and III rectal cancer. Dis Colon Rectum. 2009;52:1054–64.PubMedCrossRef Cheung WY, Neville BA, Earle CC. Etiology of delays in the initiation of adjuvant chemotherapy and their impact on outcomes for stage II and III rectal cancer. Dis Colon Rectum. 2009;52:1054–64.PubMedCrossRef
14.
go back to reference Des Guetz G, Nicolas P, Perret Gr-Y, Morere J-Fo, Uzzan B. Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. Eur J Cancer. 2010;46:1049–55.PubMedCrossRef Des Guetz G, Nicolas P, Perret Gr-Y, Morere J-Fo, Uzzan B. Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. Eur J Cancer. 2010;46:1049–55.PubMedCrossRef
15.
go back to reference Hershman D, Hall MJ, Wang X, et al. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer. 2006;107:2581–88.PubMedCrossRef Hershman D, Hall MJ, Wang X, et al. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer. 2006;107:2581–88.PubMedCrossRef
16.
go back to reference Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer. JAMA. 2011;305:2335.PubMedCrossRef Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer. JAMA. 2011;305:2335.PubMedCrossRef
17.
go back to reference Lima IS, Yasui Y, Scarfe A, Winget M. Association between receipt and timing of adjuvant chemotherapy and survival for patients with stage III colon cancer in Alberta, Canada. Cancer. 2011;117:3833–40.PubMedCrossRef Lima IS, Yasui Y, Scarfe A, Winget M. Association between receipt and timing of adjuvant chemotherapy and survival for patients with stage III colon cancer in Alberta, Canada. Cancer. 2011;117:3833–40.PubMedCrossRef
18.
go back to reference Alkis N, Durnali AG, Arslan UY, et al. Optimal timing of adjuvant treatment in patients with early breast cancer. Med Oncol. 2011;28:1255–59.PubMedCrossRef Alkis N, Durnali AG, Arslan UY, et al. Optimal timing of adjuvant treatment in patients with early breast cancer. Med Oncol. 2011;28:1255–59.PubMedCrossRef
19.
go back to reference Colleoni M, Bonetti M, Coates AS, et al. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. J Clin Oncol. 2000;18:584–84.PubMed Colleoni M, Bonetti M, Coates AS, et al. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. J Clin Oncol. 2000;18:584–84.PubMed
20.
go back to reference Lohrisch C, Paltiel C, Gelmon K, et al. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2006;24:4888–94.PubMedCrossRef Lohrisch C, Paltiel C, Gelmon K, et al. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2006;24:4888–94.PubMedCrossRef
21.
go back to reference Hristov B, Reddy S, Lin SH, et al. Outcomes of adjuvant chemoradiation after pancreaticoduodenectomy with mesenterico-portal vein resection for adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 2010;76:176–80.PubMedCrossRef Hristov B, Reddy S, Lin SH, et al. Outcomes of adjuvant chemoradiation after pancreaticoduodenectomy with mesenterico-portal vein resection for adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 2010;76:176–80.PubMedCrossRef
22.
go back to reference Kamphues C, Bova R, Schricke D, et al. Postoperative complications deteriorate long-term outcome in pancreatic cancer patients. Ann Surg Oncol. 2012;19:856–63.PubMedCrossRef Kamphues C, Bova R, Schricke D, et al. Postoperative complications deteriorate long-term outcome in pancreatic cancer patients. Ann Surg Oncol. 2012;19:856–63.PubMedCrossRef
24.
go back to reference Lerut T, Moons J, Coosemans W, et al. Postoperative complications after transthoracic esophagectomy for cancer of the esophagus and gastroesophageal junction are correlated with early cancer recurrence: role of systematic grading of complications using the modified Clavien classification. Ann Surg. 2009;250:798–07.PubMedCrossRef Lerut T, Moons J, Coosemans W, et al. Postoperative complications after transthoracic esophagectomy for cancer of the esophagus and gastroesophageal junction are correlated with early cancer recurrence: role of systematic grading of complications using the modified Clavien classification. Ann Surg. 2009;250:798–07.PubMedCrossRef
25.
go back to reference Lagarde SM, de Boer JD, ten Kate FJ, Busch OR, Obertop H, van Lanschot JJ. Postoperative complications after esophagectomy for adenocarcinoma of the esophagus are related to timing of death due to recurrence. Ann Surg. 2008;247:71–76.PubMedCrossRef Lagarde SM, de Boer JD, ten Kate FJ, Busch OR, Obertop H, van Lanschot JJ. Postoperative complications after esophagectomy for adenocarcinoma of the esophagus are related to timing of death due to recurrence. Ann Surg. 2008;247:71–76.PubMedCrossRef
26.
go back to reference Law WL, Choi HK, Lee YM, Ho JW. The impact of postoperative complications on long-term outcomes following curative resection for colorectal cancer. Ann Surg Oncol. 2007;14:2559–66.PubMedCrossRef Law WL, Choi HK, Lee YM, Ho JW. The impact of postoperative complications on long-term outcomes following curative resection for colorectal cancer. Ann Surg Oncol. 2007;14:2559–66.PubMedCrossRef
27.
go back to reference Mavros M, de Jong M, Dogeas E, Hyder O, Pawlik T. Impact of complications on long-term survival after resection of colorectal liver metastases. Br J Surg. 2013; 100:711–18.PubMedCrossRef Mavros M, de Jong M, Dogeas E, Hyder O, Pawlik T. Impact of complications on long-term survival after resection of colorectal liver metastases. Br J Surg. 2013; 100:711–18.PubMedCrossRef
28.
go back to reference McArdle C, McMillan D, Hole D. Impact of anastomotic leakage on long-term survival of patients undergoing curative resection for colorectal cancer. Br J Surg. 2005; 92:1150–54.PubMedCrossRef McArdle C, McMillan D, Hole D. Impact of anastomotic leakage on long-term survival of patients undergoing curative resection for colorectal cancer. Br J Surg. 2005; 92:1150–54.PubMedCrossRef
29.
go back to reference Petermann D, Demartines N, Schfer M. Severe postoperative complications adversely affect long-term survival after R1 resection for pancreatic head adenocarcinoma. World J Surg. 2013;37:1–8.CrossRef Petermann D, Demartines N, Schfer M. Severe postoperative complications adversely affect long-term survival after R1 resection for pancreatic head adenocarcinoma. World J Surg. 2013;37:1–8.CrossRef
30.
go back to reference Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014:32:504–12.PubMedCrossRef Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014:32:504–12.PubMedCrossRef
31.
go back to reference Merkow RP, Bilimoria KY, Tomlinson JS, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. Epub 26 Dec 2013. Merkow RP, Bilimoria KY, Tomlinson JS, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. Epub 26 Dec 2013.
32.
go back to reference Compton CC. Atlas of tumor pathology. Tumors of the pancreas. Gastroenterology. 1998; 114:614.CrossRef Compton CC. Atlas of tumor pathology. Tumors of the pancreas. Gastroenterology. 1998; 114:614.CrossRef
33.
go back to reference Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138:8–13.PubMedCrossRef Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138:8–13.PubMedCrossRef
34.
go back to reference DeOliveira ML, Winter JM, Schafer M, et al. Assessment of complications after pancreatic surgery: a novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg. 2006;244:931.PubMedCentralPubMedCrossRef DeOliveira ML, Winter JM, Schafer M, et al. Assessment of complications after pancreatic surgery: a novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg. 2006;244:931.PubMedCentralPubMedCrossRef
35.
go back to reference Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205.PubMedCentralPubMedCrossRef Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205.PubMedCentralPubMedCrossRef
36.
go back to reference Moeschberger ML, Klein JP. Survival analysis: techniques for censored and truncated data. Springer, New York; 2003. Moeschberger ML, Klein JP. Survival analysis: techniques for censored and truncated data. Springer, New York; 2003.
37.
go back to reference Cox DDR, Oakes D. Analysis of survival data. Vol. 21. CRC Press;1984. Cox DDR, Oakes D. Analysis of survival data. Vol. 21. CRC Press;1984.
38.
go back to reference Tempero MA, Arnoletti JP, Behrman SW, et al. Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012;10:703–13.PubMedCentralPubMed Tempero MA, Arnoletti JP, Behrman SW, et al. Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012;10:703–13.PubMedCentralPubMed
39.
go back to reference Hsu CC, Wolfgang CL, Laheru DA, et al. Early mortality risk score: identification of poor outcomes following upfront surgery for resectable pancreatic cancer. J Gastrointest Surg. 2012;16:753–61.PubMedCentralPubMedCrossRef Hsu CC, Wolfgang CL, Laheru DA, et al. Early mortality risk score: identification of poor outcomes following upfront surgery for resectable pancreatic cancer. J Gastrointest Surg. 2012;16:753–61.PubMedCentralPubMedCrossRef
Metadata
Title
The Impact of Postoperative Complications on the Administration of Adjuvant Therapy Following Pancreaticoduodenectomy for Adenocarcinoma
Authors
Wenchuan Wu, MD
Jin He, MD, PhD
John L. Cameron, MD
Martin Makary, MD
Kevin Soares, MD
Nita Ahuja, MD
Neda Rezaee, MD
Joseph Herman, MD
Lei Zheng, MD
Daniel Laheru, MD
Michael A. Choti, MD
Ralph H. Hruban, MD
Timothy M. Pawlik, MD, PhD, MPH
Christopher L. Wolfgang, MD, PhD
Matthew J. Weiss, MD
Publication date
01-09-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 9/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3722-6

Other articles of this Issue 9/2014

Annals of Surgical Oncology 9/2014 Go to the issue